rictor Search Results


91
Novus Biologicals rictor
Rictor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Antibody/pm22899290-48-34-40
Average 91 stars, based on 1 article reviews
rictor - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc anti rictor
Anti Rictor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Rabbit+mAb/pm41506005-121-27-29
Average 96 stars, based on 1 article reviews
anti rictor - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc 389 p70s6k
Simufilam treatment attenuated basal mTORC1 overactivation and restored its response to insulin in lymphocytes from AD subjects. Representative blot images from two AD and five healthy control subjects (A,E) show increased basal activation of mTORC1 by elevated levels of mTOR phosphorylation at S 2448 (A) and by increased basal activation of mTORC1’s downstream kinase <t>p70S6K,</t> indicated by phosphorylation at T 1389 (E) , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B,D,F) . With heightened basal activity of the mTORC1 signaling pathway in AD subject lymphocytes, its response to in vitro insulin was blunted. The elevated basal <t>p70S6K,</t> still lower than insulin-stimulated control levels, also showed a weak response to insulin. Oral simufilam treatment decreased the elevated basal mTORC1 activation and restored its response to insulin across both measures, with insulin-stimulated p70S6K levels slightly higher than untreated healthy controls on Day 28. The simufilam treatment effect is also seen in the dramatic improvement in percent stimulation by insulin (C,G) . mTOR association with Raptor was lower in healthy controls but unaffected by insulin or simufilam (D) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001, vs. respective value in healthy control by two-sided two-sample t -test; ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.
389 P70s6k, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Phospho-Rictor+(Thr1135)+Rabbit+mAb/pmc10339288-48-6-12
Average 93 stars, based on 1 article reviews
389 p70s6k - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc antirictor
Simufilam treatment attenuated basal mTORC1 overactivation and restored its response to insulin in lymphocytes from AD subjects. Representative blot images from two AD and five healthy control subjects (A,E) show increased basal activation of mTORC1 by elevated levels of mTOR phosphorylation at S 2448 (A) and by increased basal activation of mTORC1’s downstream kinase <t>p70S6K,</t> indicated by phosphorylation at T 1389 (E) , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B,D,F) . With heightened basal activity of the mTORC1 signaling pathway in AD subject lymphocytes, its response to in vitro insulin was blunted. The elevated basal <t>p70S6K,</t> still lower than insulin-stimulated control levels, also showed a weak response to insulin. Oral simufilam treatment decreased the elevated basal mTORC1 activation and restored its response to insulin across both measures, with insulin-stimulated p70S6K levels slightly higher than untreated healthy controls on Day 28. The simufilam treatment effect is also seen in the dramatic improvement in percent stimulation by insulin (C,G) . mTOR association with Raptor was lower in healthy controls but unaffected by insulin or simufilam (D) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001, vs. respective value in healthy control by two-sided two-sample t -test; ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.
Antirictor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Rabbit+mAb/10__1016_slash_j__jff__2023__105948-92-18-21
Average 95 stars, based on 1 article reviews
antirictor - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rictor
DL001 selectively inhibits mTORC1 in vivo. a – d Protein lysates were prepared from the a liver, b gastrocnemius, and c heart of female C57BL/6J mice treated with vehicle or 13 mg kg −1 DL001 every other day for 20 days, and the phosphorylation of S240/S244 S6 (a readout for mTORC1 activity) and Akt S473, an mTORC2 substrate, was determined by western blotting. d The activity of DL001 and rapamycin against mTORC1 and mTORC2 was determined by quantification of the western blots above and from mice treated in parallel with 8 mg kg −1 rapamycin 30 using NIH ImageJ ( n = 4 biologically independent animals per group, * p < 0.05, Tukey–Kramer test following one-way ANOVA). Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. e , f C57BL/6J mice were treated with either vehicle, 8 mg kg −1 rapamycin or 12 mg kg −1 DL001 every other day for 5 weeks. e Quantification of phosphorylated liver proteins in vehicle, rapamycin, and DL001-treated mice ( n = 17 vehicle, 16 rapamycin, and 9 DL001-treated biologically independent animals for quantification of phosphorylated S6 and S6K1, 12 vehicle, 10 rapamycin, and 6 DL0001-treated biologically independent animals for quantification of <t>phosphorylated</t> <t>ULK1;</t> Dunnett’s test following one-way ANOVA, * p < 0.05). f The integrity of mTORC2 was determined by immunoprecipitation of <t>Rictor</t> from liver lysate; the immunoprecipitate and lysate were probed with antibodies against the indicated proteins and quantified with NIH ImageJ. mTOR(IP) and RICTOR(IP) refer to the quantification of the mTOR and RICTOR immunoblots from the RICTOR immunoprecipitate ( n = 6 vehicle, 5 rapamycin, and 3 DL001-treated biologically independent animals, * p < 0.05, Tukey–Kramer test following one-way ANOVA). e , f Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. Error bars represent standard error. Source data are provided as a Source Data file
Rictor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Antibody/pmc06642166-132-44-58
Average 96 stars, based on 1 article reviews
rictor - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sirna rictor
DL001 selectively inhibits mTORC1 in vivo. a – d Protein lysates were prepared from the a liver, b gastrocnemius, and c heart of female C57BL/6J mice treated with vehicle or 13 mg kg −1 DL001 every other day for 20 days, and the phosphorylation of S240/S244 S6 (a readout for mTORC1 activity) and Akt S473, an mTORC2 substrate, was determined by western blotting. d The activity of DL001 and rapamycin against mTORC1 and mTORC2 was determined by quantification of the western blots above and from mice treated in parallel with 8 mg kg −1 rapamycin 30 using NIH ImageJ ( n = 4 biologically independent animals per group, * p < 0.05, Tukey–Kramer test following one-way ANOVA). Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. e , f C57BL/6J mice were treated with either vehicle, 8 mg kg −1 rapamycin or 12 mg kg −1 DL001 every other day for 5 weeks. e Quantification of phosphorylated liver proteins in vehicle, rapamycin, and DL001-treated mice ( n = 17 vehicle, 16 rapamycin, and 9 DL001-treated biologically independent animals for quantification of phosphorylated S6 and S6K1, 12 vehicle, 10 rapamycin, and 6 DL0001-treated biologically independent animals for quantification of <t>phosphorylated</t> <t>ULK1;</t> Dunnett’s test following one-way ANOVA, * p < 0.05). f The integrity of mTORC2 was determined by immunoprecipitation of <t>Rictor</t> from liver lysate; the immunoprecipitate and lysate were probed with antibodies against the indicated proteins and quantified with NIH ImageJ. mTOR(IP) and RICTOR(IP) refer to the quantification of the mTOR and RICTOR immunoblots from the RICTOR immunoprecipitate ( n = 6 vehicle, 5 rapamycin, and 3 DL001-treated biologically independent animals, * p < 0.05, Tukey–Kramer test following one-way ANOVA). e , f Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. Error bars represent standard error. Source data are provided as a Source Data file
Sirna Rictor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+siRNA/10__1161_slash_circulationaha__113__004581-149-53-70
Average 93 stars, based on 1 article reviews
sirna rictor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology primary antibodies for rictor
Fig. 1. JR-AB2-011 inhibits the increased protein expression and/or phosphorylation of <t>rictor</t> <t>and</t> <t>Akt</t> in IL-1β-treated chondrocytes. The chondrocytes were treated with IL-1β (2 ng/ml) with or without JR- AB2-011 (50, 100, and 250 μM) for 24 h. The density of bands was analyzed using Image J 1.54d software. The values are presented as the means ± SEM. * p < 0.05 versus control group; # p < 0.05 versus IL-1β alone group.
Primary Antibodies For Rictor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Antibody/pm39380280-38-0-39
Average 93 stars, based on 1 article reviews
primary antibodies for rictor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Fortis Life Sciences rictor
Ablation of fibroblast <t>Rictor</t> aggravates kidney ischemia/reperfusion injury in mice. a The strategy for inducing fibroblast Rictor gene deletion in Gli1-Cre+/−, Rictorfl/fl mice and renal IRI surgery. b Representative micrographs showing the ablation of Rictor in Gli1+ cells in IRI kidneys from Gli1+-Rictor−/− mice. The asterisk indicates both Gli1- and Rictor-positive cells in Rictor+/+ kidneys. The white arrow indicates Gli1-positive but Rictor-negative cells in the knockout kidneys. Scale bar = 10 µm. c The graph showing blood urea nitrogen (BUN) level in Gli1+-Rictor+/+ and Gli1+-Rictor−/− mice at 1 day after IRI. *P < 0.05, n = 10. d Kidney histology as shown by PAS staining. Representative immunofluorescent staining images for Ly6b and CD3 among groups as indicated. Scale bar = 50 µm. e Representative immunofluorescent staining images for <t>cleaved</t> <t>caspase</t> 3 and TUNEL staining for apoptotic cells among groups as indicated. f The graph showing the injury scores among groups. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6. Each dot represents the average of five HPFs from each mouse. g, h Quantitative determination of Ly6b+ cells and CD3+ cells among groups as indicated. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 5–6. Each dot represents the average of four HPFs from each mouse. i Real-time qRT-PCR analysis showing the mRNA abundance for Rantes, Mcp-1, and Tnf-α in Rictor+/+ and the knockout kidneys at day 1 after IRI. *P < 0.05 versus Rictor+/+ mice after IRI, n = 6. j, k Quantitative determination of cleaved caspase 3+ cells and TUNEL+ cells. *P < 0.05 versus Rictor+/+ mice, n = 3–7; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6–7. Each dot represents the average of five HPFs from each mouse
Rictor, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Rictor+Antibody/pmc07224397-65-52-55
Average 93 stars, based on 1 article reviews
rictor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc proteins transient expression myc rictor
Ablation of fibroblast <t>Rictor</t> aggravates kidney ischemia/reperfusion injury in mice. a The strategy for inducing fibroblast Rictor gene deletion in Gli1-Cre+/−, Rictorfl/fl mice and renal IRI surgery. b Representative micrographs showing the ablation of Rictor in Gli1+ cells in IRI kidneys from Gli1+-Rictor−/− mice. The asterisk indicates both Gli1- and Rictor-positive cells in Rictor+/+ kidneys. The white arrow indicates Gli1-positive but Rictor-negative cells in the knockout kidneys. Scale bar = 10 µm. c The graph showing blood urea nitrogen (BUN) level in Gli1+-Rictor+/+ and Gli1+-Rictor−/− mice at 1 day after IRI. *P < 0.05, n = 10. d Kidney histology as shown by PAS staining. Representative immunofluorescent staining images for Ly6b and CD3 among groups as indicated. Scale bar = 50 µm. e Representative immunofluorescent staining images for <t>cleaved</t> <t>caspase</t> 3 and TUNEL staining for apoptotic cells among groups as indicated. f The graph showing the injury scores among groups. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6. Each dot represents the average of five HPFs from each mouse. g, h Quantitative determination of Ly6b+ cells and CD3+ cells among groups as indicated. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 5–6. Each dot represents the average of four HPFs from each mouse. i Real-time qRT-PCR analysis showing the mRNA abundance for Rantes, Mcp-1, and Tnf-α in Rictor+/+ and the knockout kidneys at day 1 after IRI. *P < 0.05 versus Rictor+/+ mice after IRI, n = 6. j, k Quantitative determination of cleaved caspase 3+ cells and TUNEL+ cells. *P < 0.05 versus Rictor+/+ mice, n = 3–7; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6–7. Each dot represents the average of five HPFs from each mouse
Proteins Transient Expression Myc Rictor, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/myc-Rictor+corrected+(Plasmid+%2311367)/pm31653780-152-5-25
Average 93 stars, based on 1 article reviews
proteins transient expression myc rictor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc rictor expression vector
Osteoblast adhesion and survival are markedly reduced and <t>Rictor</t> <t>expression</t> is downregulated with aging in vitro and in vivo . ( a ) Representative immunohistochemical (IHC) staining for osteocalcin (OCN) from 3-month-old and 16-month-old mice ( n =6). Arrow, osteoblast; BS, bone surface; scale bar, 50 μ m; * P <0.01 versus 3M. ( b ) SEM image of femora trabecular bones from 3- and 16-month-old mice. Upper panel showed less and thinner trabecula bone in 16-month-old mice. Black arrow, osteoblasts or osteocytes, up panel scale bar, 500 μ m; lower panel scale bar, 50 μ m. ( c ) Photomicrographs of fluorescent calcein staining of 3- and 16-month-old mice and quantification of mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR) and MAR/osteoblast. Arrow: bone formation surface; scale bar, 20 μ m ( n =3 * P <0.01 versus 3M). ( d ) Cell adhesion analyses of calvarial osteoblast cultures from 3- and 16-month-old mice with (lower panel) or without (upper panel) matrigel in the plate ( n =3 * P <0.01 versus 3M). ( e ) Representative photomicrographs of bone nodule formation in MSC cultures from 3- and 16-month-old mice. Scale bar, 400 μ m. ( f ) Western blot analysis of cleaved-poly ADP-ribose polymerase (PARP) in lysates of trabecular bone dissected from femora of 3- and 16-month-old mice. ( g ) Western blot analysis of Rictor and P-Akt(S473) expression in lysates of trabecular bone from 3- and 16-month-old mice. ( h ) Western blot analysis of mTOR, Rictor, Raptor and P-Akt(S473) expression in lysates of lung, spleen and kidney from 3- and 16-month-old mice. ( i ) Western blot analysis of Rictor, mTOR, Raptor, osteocalcin (OCN) and P-Akt(S473) expression in primary calvarial osteoblasts from 3- and 16-month-old mice
Rictor Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/myc-Rictor+(Plasmid+%231860)/pmc05133960-124-5-9
Average 93 stars, based on 1 article reviews
rictor expression vector - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

88
Atlas Antibodies antibodies against rictor
Figure 3. mTORC2, AKT, and GSK3b Signaling Components Are Present in Mitochondria-ER Junctions (A) Immunoblots of MEJ, PM, and EGC fractions and total lysate (T) from Jurkat T cells. Blots were probed with mTOR, <t>RICTOR,</t> RAPTOR, and <t>AKT</t> <t>antibodies.</t> COX IV was used as loading and fraction-validation control (representative of n = 3 independent experiments). (B) Immunoblots of EGC and MEJ fractions from NV and EM human CD8+ T cells probed with antibodies specific for RICTOR and mTOR. GRP75 was used to validate the respective fractions (representative of n = 2 independent samples, each sample consisted of 4 3 107 sorted cells, pooled from 2–4 donors). (C) Immunoblot analysis of EGC and MEJ fractions from bulk CD8+ T cells treated with non-loaded control beads (–) or activated with a-CD3 and a-CD28 mAb-loaded beads (+) for 2 hr. Blots were probed with mTOR and RICTOR antibodies. Cox IV was used as fraction validation control (representative of n = 3 independent experiments). (D) Left, immunoblot analysis of MEJ fractions from wild-type (WT) and rictor KO memory CD8+ T cells re-stimulated with OVA peptide for 1 hr (+) or from non-activated counterparts (–). Blots were probed for total Akt, pAkt-S473, pAkt-T308, and Cox IV. Right, quantification was performed by normalization of targets to Cox IV. Bar graphs show fold change in Akt phosphorylation following activation relative to non-activated controls (n = 3 independent experiments). (E and F) Summary of metabolic flux analysis on EM CD8+ T cells activated and assayed as in Figure 1A. Cells were treated with inhibitors of mTOR (OSI-027, 10 mM, and KU0063794, 10 mM) (E) or AKT (Akti, 10 mM, and MK2206, 10 mM) (F). Bar graphs show basal and maximal respiration (n = 4–8 donors). (G) Immunoblot analysis of total cell lysates from EM CD8+ T cells activated for 2 hr with a-CD3 and a-CD28 mAb loaded beads only or similarly activated in presence of nocodazole (10 mM). Bar graph shows AKT-Ser473 phosphorylation normalized to actin (n = 3 independent experiments). (H) Immunoblots of MEJ and PM fractions from Jurkat T cells. Blots were probed with GSK3b and COX IV antibodies (representative of n = 3 independent experiments). (I) Immunoblots of MEJ and EGC fractions from bulk CD8+ T cells either left unstimulated (–) or activated (+) with a-CD3 and a-CD28 mAb-loaded beads for 2 hr. Blots were probed for total GSK3b, pGSK3b Ser9, and COX IV (representative of n = 3 donors). (J) Left, immunoblot analysis of WT and rictor KO memory OT-I cells activated as in (D). MEJ fractions were probed for Gsk-3b, pGsk-3b Ser9, and Cox IV. Right, bar graphs display fold change in phosphoprotein levels relative to non-activated controls (n = 3 independent experiments). Data are presented as mean ± SEM. Two-tailed paired Student’s t test (D–G, J) were used to compare groups. *p < 0.05, **p < 0.01, ns, not significant. See also Figure S3.
Antibodies Against Rictor, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/Anti-RICTOR/pm29523440-362-4-7
Average 88 stars, based on 1 article reviews
antibodies against rictor - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

93
Proteintech anti rictor antibody
Figure 3. mTORC2, AKT, and GSK3b Signaling Components Are Present in Mitochondria-ER Junctions (A) Immunoblots of MEJ, PM, and EGC fractions and total lysate (T) from Jurkat T cells. Blots were probed with mTOR, <t>RICTOR,</t> RAPTOR, and <t>AKT</t> <t>antibodies.</t> COX IV was used as loading and fraction-validation control (representative of n = 3 independent experiments). (B) Immunoblots of EGC and MEJ fractions from NV and EM human CD8+ T cells probed with antibodies specific for RICTOR and mTOR. GRP75 was used to validate the respective fractions (representative of n = 2 independent samples, each sample consisted of 4 3 107 sorted cells, pooled from 2–4 donors). (C) Immunoblot analysis of EGC and MEJ fractions from bulk CD8+ T cells treated with non-loaded control beads (–) or activated with a-CD3 and a-CD28 mAb-loaded beads (+) for 2 hr. Blots were probed with mTOR and RICTOR antibodies. Cox IV was used as fraction validation control (representative of n = 3 independent experiments). (D) Left, immunoblot analysis of MEJ fractions from wild-type (WT) and rictor KO memory CD8+ T cells re-stimulated with OVA peptide for 1 hr (+) or from non-activated counterparts (–). Blots were probed for total Akt, pAkt-S473, pAkt-T308, and Cox IV. Right, quantification was performed by normalization of targets to Cox IV. Bar graphs show fold change in Akt phosphorylation following activation relative to non-activated controls (n = 3 independent experiments). (E and F) Summary of metabolic flux analysis on EM CD8+ T cells activated and assayed as in Figure 1A. Cells were treated with inhibitors of mTOR (OSI-027, 10 mM, and KU0063794, 10 mM) (E) or AKT (Akti, 10 mM, and MK2206, 10 mM) (F). Bar graphs show basal and maximal respiration (n = 4–8 donors). (G) Immunoblot analysis of total cell lysates from EM CD8+ T cells activated for 2 hr with a-CD3 and a-CD28 mAb loaded beads only or similarly activated in presence of nocodazole (10 mM). Bar graph shows AKT-Ser473 phosphorylation normalized to actin (n = 3 independent experiments). (H) Immunoblots of MEJ and PM fractions from Jurkat T cells. Blots were probed with GSK3b and COX IV antibodies (representative of n = 3 independent experiments). (I) Immunoblots of MEJ and EGC fractions from bulk CD8+ T cells either left unstimulated (–) or activated (+) with a-CD3 and a-CD28 mAb-loaded beads for 2 hr. Blots were probed for total GSK3b, pGSK3b Ser9, and COX IV (representative of n = 3 donors). (J) Left, immunoblot analysis of WT and rictor KO memory OT-I cells activated as in (D). MEJ fractions were probed for Gsk-3b, pGsk-3b Ser9, and Cox IV. Right, bar graphs display fold change in phosphoprotein levels relative to non-activated controls (n = 3 independent experiments). Data are presented as mean ± SEM. Two-tailed paired Student’s t test (D–G, J) were used to compare groups. *p < 0.05, **p < 0.01, ns, not significant. See also Figure S3.
Anti Rictor Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rictor/RICTOR+Antibody/pm41559041-385-49-130
Average 93 stars, based on 1 article reviews
anti rictor antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Simufilam treatment attenuated basal mTORC1 overactivation and restored its response to insulin in lymphocytes from AD subjects. Representative blot images from two AD and five healthy control subjects (A,E) show increased basal activation of mTORC1 by elevated levels of mTOR phosphorylation at S 2448 (A) and by increased basal activation of mTORC1’s downstream kinase p70S6K, indicated by phosphorylation at T 1389 (E) , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B,D,F) . With heightened basal activity of the mTORC1 signaling pathway in AD subject lymphocytes, its response to in vitro insulin was blunted. The elevated basal p70S6K, still lower than insulin-stimulated control levels, also showed a weak response to insulin. Oral simufilam treatment decreased the elevated basal mTORC1 activation and restored its response to insulin across both measures, with insulin-stimulated p70S6K levels slightly higher than untreated healthy controls on Day 28. The simufilam treatment effect is also seen in the dramatic improvement in percent stimulation by insulin (C,G) . mTOR association with Raptor was lower in healthy controls but unaffected by insulin or simufilam (D) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001, vs. respective value in healthy control by two-sided two-sample t -test; ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.

Journal: Frontiers in Aging

Article Title: Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes

doi: 10.3389/fragi.2023.1175601

Figure Lengend Snippet: Simufilam treatment attenuated basal mTORC1 overactivation and restored its response to insulin in lymphocytes from AD subjects. Representative blot images from two AD and five healthy control subjects (A,E) show increased basal activation of mTORC1 by elevated levels of mTOR phosphorylation at S 2448 (A) and by increased basal activation of mTORC1’s downstream kinase p70S6K, indicated by phosphorylation at T 1389 (E) , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B,D,F) . With heightened basal activity of the mTORC1 signaling pathway in AD subject lymphocytes, its response to in vitro insulin was blunted. The elevated basal p70S6K, still lower than insulin-stimulated control levels, also showed a weak response to insulin. Oral simufilam treatment decreased the elevated basal mTORC1 activation and restored its response to insulin across both measures, with insulin-stimulated p70S6K levels slightly higher than untreated healthy controls on Day 28. The simufilam treatment effect is also seen in the dramatic improvement in percent stimulation by insulin (C,G) . mTOR association with Raptor was lower in healthy controls but unaffected by insulin or simufilam (D) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001, vs. respective value in healthy control by two-sided two-sample t -test; ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.

Article Snippet: Anti-pT 1135 Rictor (#3806) and -pT 389 p70S6K (#9205) were purchased from Cell Signaling Technology.

Techniques: Control, Activation Assay, Phospho-proteomics, Quantitation Assay, Activity Assay, In Vitro

Simufilam treatment attenuates mTORC2-mediated Akt1 activation. Akt1 is activated by mTORC2 signaling by phosphorylation on S 473 to further activate mTORC1. Representative blot images from two AD and five healthy control subjects (A) show increased basal Akt1 activation, as indicated by its phosphorylation at S 473 , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B) . Showing a similar pattern to downstream effectors p70S6K and pT 1135 Rictor, basal Akt1 activity was elevated in AD subjects without nearing insulin-stimulated control levels, and its response to insulin was still blunted. Oral simufilam treatment decreased the elevated Akt1 activation and restored its response to insulin to a level not different from healthy control. Percent stimulation of Akt1 by insulin improved dramatically after simufilam treatment (C) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001 vs. respective value in healthy control by two-sided two-sample t -test; # p < 0.05, ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.

Journal: Frontiers in Aging

Article Title: Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes

doi: 10.3389/fragi.2023.1175601

Figure Lengend Snippet: Simufilam treatment attenuates mTORC2-mediated Akt1 activation. Akt1 is activated by mTORC2 signaling by phosphorylation on S 473 to further activate mTORC1. Representative blot images from two AD and five healthy control subjects (A) show increased basal Akt1 activation, as indicated by its phosphorylation at S 473 , in AD subjects versus healthy controls. Blots were analyzed by densitometric quantitation (B) . Showing a similar pattern to downstream effectors p70S6K and pT 1135 Rictor, basal Akt1 activity was elevated in AD subjects without nearing insulin-stimulated control levels, and its response to insulin was still blunted. Oral simufilam treatment decreased the elevated Akt1 activation and restored its response to insulin to a level not different from healthy control. Percent stimulation of Akt1 by insulin improved dramatically after simufilam treatment (C) . Data are means ± SEM. N = 13 for AD, 18 for control. * p < 0.05, *** p < 0.001 vs. respective value in healthy control by two-sided two-sample t -test; # p < 0.05, ### p < 0.001 vs. respective AD value at Day 0 by two-sided paired t -test.

Article Snippet: Anti-pT 1135 Rictor (#3806) and -pT 389 p70S6K (#9205) were purchased from Cell Signaling Technology.

Techniques: Activation Assay, Phospho-proteomics, Control, Quantitation Assay, Activity Assay

DL001 selectively inhibits mTORC1 in vivo. a – d Protein lysates were prepared from the a liver, b gastrocnemius, and c heart of female C57BL/6J mice treated with vehicle or 13 mg kg −1 DL001 every other day for 20 days, and the phosphorylation of S240/S244 S6 (a readout for mTORC1 activity) and Akt S473, an mTORC2 substrate, was determined by western blotting. d The activity of DL001 and rapamycin against mTORC1 and mTORC2 was determined by quantification of the western blots above and from mice treated in parallel with 8 mg kg −1 rapamycin 30 using NIH ImageJ ( n = 4 biologically independent animals per group, * p < 0.05, Tukey–Kramer test following one-way ANOVA). Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. e , f C57BL/6J mice were treated with either vehicle, 8 mg kg −1 rapamycin or 12 mg kg −1 DL001 every other day for 5 weeks. e Quantification of phosphorylated liver proteins in vehicle, rapamycin, and DL001-treated mice ( n = 17 vehicle, 16 rapamycin, and 9 DL001-treated biologically independent animals for quantification of phosphorylated S6 and S6K1, 12 vehicle, 10 rapamycin, and 6 DL0001-treated biologically independent animals for quantification of phosphorylated ULK1; Dunnett’s test following one-way ANOVA, * p < 0.05). f The integrity of mTORC2 was determined by immunoprecipitation of Rictor from liver lysate; the immunoprecipitate and lysate were probed with antibodies against the indicated proteins and quantified with NIH ImageJ. mTOR(IP) and RICTOR(IP) refer to the quantification of the mTOR and RICTOR immunoblots from the RICTOR immunoprecipitate ( n = 6 vehicle, 5 rapamycin, and 3 DL001-treated biologically independent animals, * p < 0.05, Tukey–Kramer test following one-way ANOVA). e , f Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. Error bars represent standard error. Source data are provided as a Source Data file

Journal: Nature Communications

Article Title: A novel rapamycin analog is highly selective for mTORC1 in vivo

doi: 10.1038/s41467-019-11174-0

Figure Lengend Snippet: DL001 selectively inhibits mTORC1 in vivo. a – d Protein lysates were prepared from the a liver, b gastrocnemius, and c heart of female C57BL/6J mice treated with vehicle or 13 mg kg −1 DL001 every other day for 20 days, and the phosphorylation of S240/S244 S6 (a readout for mTORC1 activity) and Akt S473, an mTORC2 substrate, was determined by western blotting. d The activity of DL001 and rapamycin against mTORC1 and mTORC2 was determined by quantification of the western blots above and from mice treated in parallel with 8 mg kg −1 rapamycin 30 using NIH ImageJ ( n = 4 biologically independent animals per group, * p < 0.05, Tukey–Kramer test following one-way ANOVA). Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. e , f C57BL/6J mice were treated with either vehicle, 8 mg kg −1 rapamycin or 12 mg kg −1 DL001 every other day for 5 weeks. e Quantification of phosphorylated liver proteins in vehicle, rapamycin, and DL001-treated mice ( n = 17 vehicle, 16 rapamycin, and 9 DL001-treated biologically independent animals for quantification of phosphorylated S6 and S6K1, 12 vehicle, 10 rapamycin, and 6 DL0001-treated biologically independent animals for quantification of phosphorylated ULK1; Dunnett’s test following one-way ANOVA, * p < 0.05). f The integrity of mTORC2 was determined by immunoprecipitation of Rictor from liver lysate; the immunoprecipitate and lysate were probed with antibodies against the indicated proteins and quantified with NIH ImageJ. mTOR(IP) and RICTOR(IP) refer to the quantification of the mTOR and RICTOR immunoblots from the RICTOR immunoprecipitate ( n = 6 vehicle, 5 rapamycin, and 3 DL001-treated biologically independent animals, * p < 0.05, Tukey–Kramer test following one-way ANOVA). e , f Data from Vehicle-treated mice are plotted with white bars, rapamycin-treated mice with black bars, and DL001-treated mice with red bars. Error bars represent standard error. Source data are provided as a Source Data file

Article Snippet: For western blotting, antibodies to phospho-AKT S473 (4060), AKT (4691), phospho-p70 S6 kinase (9234), p70 S6 kinase (2708), phospho-S6 ribosomal protein (2215 or 5364), S6 ribosomal protein (2217), p-4EBP1 S65 (9451), p-4EBP1 T37/S46 (2855), total 4EBP1 (9452), p-S757 ULK1 (14202), ULK1 (8054), mTOR (2792), RICTOR (2140), HSP90 (4877), β-tubulin (2128S), FKBP51 (12210S), and p-PKA substrate (9621) were from Cell Signaling Technology; β-actin (A2228) was from Sigma; ATGL (SC-365278) was from Santa Cruz; and FKBP12 (ab2918) was from Abcam.

Techniques: In Vivo, Phospho-proteomics, Activity Assay, Western Blot, Immunoprecipitation

Fig. 1. JR-AB2-011 inhibits the increased protein expression and/or phosphorylation of rictor and Akt in IL-1β-treated chondrocytes. The chondrocytes were treated with IL-1β (2 ng/ml) with or without JR- AB2-011 (50, 100, and 250 μM) for 24 h. The density of bands was analyzed using Image J 1.54d software. The values are presented as the means ± SEM. * p < 0.05 versus control group; # p < 0.05 versus IL-1β alone group.

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Article Title: mTORC2 inhibition by JR-AB2-011 improves IL-1β-induced inflammation, catabolic response, and apoptosis in human chondrocytes through IκB-α/NF-κB p65.

doi: 10.14715/cmb/2024.70.9.5

Figure Lengend Snippet: Fig. 1. JR-AB2-011 inhibits the increased protein expression and/or phosphorylation of rictor and Akt in IL-1β-treated chondrocytes. The chondrocytes were treated with IL-1β (2 ng/ml) with or without JR- AB2-011 (50, 100, and 250 μM) for 24 h. The density of bands was analyzed using Image J 1.54d software. The values are presented as the means ± SEM. * p < 0.05 versus control group; # p < 0.05 versus IL-1β alone group.

Article Snippet: Primary antibodies for rictor (SC-271081), p-Akt Ser473 (SC-293125), Akt (SC-5298), IκB-α (SC-1643,), p-IκB-α Ser32 (SC-7977), NF-κB p65 (SC-8008), p-NF-κB p65 (SC-33020), TNF-α (SC-33639), IL-6 (SC-32296), MMP13 (MA5-14247), iNOS (SC-7271), Bax (SC23959), caspase3 (SC-56053), and β-actin (SC-47778) were purchased from Santa Cruz Biotechnology (Texas, USA) and Invitrogen (Massachusetts, USA).

Techniques: Expressing, Phospho-proteomics, Software, Control

Ablation of fibroblast Rictor aggravates kidney ischemia/reperfusion injury in mice. a The strategy for inducing fibroblast Rictor gene deletion in Gli1-Cre+/−, Rictorfl/fl mice and renal IRI surgery. b Representative micrographs showing the ablation of Rictor in Gli1+ cells in IRI kidneys from Gli1+-Rictor−/− mice. The asterisk indicates both Gli1- and Rictor-positive cells in Rictor+/+ kidneys. The white arrow indicates Gli1-positive but Rictor-negative cells in the knockout kidneys. Scale bar = 10 µm. c The graph showing blood urea nitrogen (BUN) level in Gli1+-Rictor+/+ and Gli1+-Rictor−/− mice at 1 day after IRI. *P < 0.05, n = 10. d Kidney histology as shown by PAS staining. Representative immunofluorescent staining images for Ly6b and CD3 among groups as indicated. Scale bar = 50 µm. e Representative immunofluorescent staining images for cleaved caspase 3 and TUNEL staining for apoptotic cells among groups as indicated. f The graph showing the injury scores among groups. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6. Each dot represents the average of five HPFs from each mouse. g, h Quantitative determination of Ly6b+ cells and CD3+ cells among groups as indicated. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 5–6. Each dot represents the average of four HPFs from each mouse. i Real-time qRT-PCR analysis showing the mRNA abundance for Rantes, Mcp-1, and Tnf-α in Rictor+/+ and the knockout kidneys at day 1 after IRI. *P < 0.05 versus Rictor+/+ mice after IRI, n = 6. j, k Quantitative determination of cleaved caspase 3+ cells and TUNEL+ cells. *P < 0.05 versus Rictor+/+ mice, n = 3–7; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6–7. Each dot represents the average of five HPFs from each mouse

Journal: Cell Death and Differentiation

Article Title: Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury

doi: 10.1038/s41418-019-0336-3

Figure Lengend Snippet: Ablation of fibroblast Rictor aggravates kidney ischemia/reperfusion injury in mice. a The strategy for inducing fibroblast Rictor gene deletion in Gli1-Cre+/−, Rictorfl/fl mice and renal IRI surgery. b Representative micrographs showing the ablation of Rictor in Gli1+ cells in IRI kidneys from Gli1+-Rictor−/− mice. The asterisk indicates both Gli1- and Rictor-positive cells in Rictor+/+ kidneys. The white arrow indicates Gli1-positive but Rictor-negative cells in the knockout kidneys. Scale bar = 10 µm. c The graph showing blood urea nitrogen (BUN) level in Gli1+-Rictor+/+ and Gli1+-Rictor−/− mice at 1 day after IRI. *P < 0.05, n = 10. d Kidney histology as shown by PAS staining. Representative immunofluorescent staining images for Ly6b and CD3 among groups as indicated. Scale bar = 50 µm. e Representative immunofluorescent staining images for cleaved caspase 3 and TUNEL staining for apoptotic cells among groups as indicated. f The graph showing the injury scores among groups. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6. Each dot represents the average of five HPFs from each mouse. g, h Quantitative determination of Ly6b+ cells and CD3+ cells among groups as indicated. *P < 0.05 versus Rictor+/+ mice, n = 3–6; #P < 0.05 versus Rictor+/+ mice after IRI, n = 5–6. Each dot represents the average of four HPFs from each mouse. i Real-time qRT-PCR analysis showing the mRNA abundance for Rantes, Mcp-1, and Tnf-α in Rictor+/+ and the knockout kidneys at day 1 after IRI. *P < 0.05 versus Rictor+/+ mice after IRI, n = 6. j, k Quantitative determination of cleaved caspase 3+ cells and TUNEL+ cells. *P < 0.05 versus Rictor+/+ mice, n = 3–7; #P < 0.05 versus Rictor+/+ mice after IRI, n = 6–7. Each dot represents the average of five HPFs from each mouse

Article Snippet: After blocking with 2% normal donkey serum for 60 min, the slides were immunostained with antibodies against Gli1 (cat: 388516, RD Systems), Fsp1 (cat: NB100-55404, Novus), PDGFRβ (cat:14-1402, eBioscience), p-Akt (Ser473) (cat: 3868, Cell Signaling Technology), p-S6 (cat: 4858, Cell Signaling Technology), Rheb (cat: ab25873, abcam), Tsc1 (cat: 4906, Cell Signaling Technology), Rictor (cat: A300-459A, Bethyl Laboratories), cleaved caspase 3 (cat: 9664, Cell Signaling Technology), Ly6b (cat: MCA771G, AbD Serotec, Raleigh, NC), and CD3 (cat: 555273, BD Pharmingen), respectively.

Techniques: Knock-Out, Staining, TUNEL Assay, Quantitative RT-PCR

Fibroblast mTORC1 and mTORC2 activation protects against staurosporine-induced tubular cell apoptosis. a The coculture system of tubular cells and kidney fibroblasts. b–d Western blot assay showing the abundance for Rheb, Tsc1, and Rictor in kidney fibroblasts. Primary cultured kidney fibroblasts generated from Rhebfl/fl, Tsc1fl/fl, and Rictorfl/fl mice were infected with adeno-Cre for 48 h to induce Rheb, Tsc1, and Rictor gene ablation, respectively. Fibroblasts infected with adeno-GFP were used as control fibroblasts. e–g Western blotting analyses showing the abundance of cleaved caspase 3 in primary cultured tubular cells incubated with CM from various primary cultured kidney fibroblasts as indicated. Tubular cells were treated with staurosporine (1 μM) for different duration. h–j Representative immunofluorescent staining images for cleaved caspase 3 among groups as indicated. Tubular cells were treated with staurosporine (1 μM) for 3 h. Scale bar = 20 µm. k–m Quantitative determination of cleaved caspase 3+ cells among groups as indicated. Data are presented as the percentage of the counted cells. *P < 0.05 versus vehicle-treated Rheb+/+ fibroblasts, n = 4; #P < 0.05 versus staurosporine-treated Rheb+/+ fibroblasts, n = 4. n = 4 refers to four independent repeats (k); *P < 0.05 versus vehicle-treated Tsc1+/+ fibroblasts, n = 3; #P < 0.05 versus staurosporine-treated Tsc1+/+ fibroblasts, n = 3. n = 3 refers to three independent repeats (l); *P < 0.05 versus vehicle-treated Rictor+/+ fibroblasts, n = 3; #P < 0.05 versus staurosporine-treated Rictor+/+ fibroblasts, n = 3. n = 3 refers to three independent repeats (m). CM conditioned media

Journal: Cell Death and Differentiation

Article Title: Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury

doi: 10.1038/s41418-019-0336-3

Figure Lengend Snippet: Fibroblast mTORC1 and mTORC2 activation protects against staurosporine-induced tubular cell apoptosis. a The coculture system of tubular cells and kidney fibroblasts. b–d Western blot assay showing the abundance for Rheb, Tsc1, and Rictor in kidney fibroblasts. Primary cultured kidney fibroblasts generated from Rhebfl/fl, Tsc1fl/fl, and Rictorfl/fl mice were infected with adeno-Cre for 48 h to induce Rheb, Tsc1, and Rictor gene ablation, respectively. Fibroblasts infected with adeno-GFP were used as control fibroblasts. e–g Western blotting analyses showing the abundance of cleaved caspase 3 in primary cultured tubular cells incubated with CM from various primary cultured kidney fibroblasts as indicated. Tubular cells were treated with staurosporine (1 μM) for different duration. h–j Representative immunofluorescent staining images for cleaved caspase 3 among groups as indicated. Tubular cells were treated with staurosporine (1 μM) for 3 h. Scale bar = 20 µm. k–m Quantitative determination of cleaved caspase 3+ cells among groups as indicated. Data are presented as the percentage of the counted cells. *P < 0.05 versus vehicle-treated Rheb+/+ fibroblasts, n = 4; #P < 0.05 versus staurosporine-treated Rheb+/+ fibroblasts, n = 4. n = 4 refers to four independent repeats (k); *P < 0.05 versus vehicle-treated Tsc1+/+ fibroblasts, n = 3; #P < 0.05 versus staurosporine-treated Tsc1+/+ fibroblasts, n = 3. n = 3 refers to three independent repeats (l); *P < 0.05 versus vehicle-treated Rictor+/+ fibroblasts, n = 3; #P < 0.05 versus staurosporine-treated Rictor+/+ fibroblasts, n = 3. n = 3 refers to three independent repeats (m). CM conditioned media

Article Snippet: After blocking with 2% normal donkey serum for 60 min, the slides were immunostained with antibodies against Gli1 (cat: 388516, RD Systems), Fsp1 (cat: NB100-55404, Novus), PDGFRβ (cat:14-1402, eBioscience), p-Akt (Ser473) (cat: 3868, Cell Signaling Technology), p-S6 (cat: 4858, Cell Signaling Technology), Rheb (cat: ab25873, abcam), Tsc1 (cat: 4906, Cell Signaling Technology), Rictor (cat: A300-459A, Bethyl Laboratories), cleaved caspase 3 (cat: 9664, Cell Signaling Technology), Ly6b (cat: MCA771G, AbD Serotec, Raleigh, NC), and CD3 (cat: 555273, BD Pharmingen), respectively.

Techniques: Activation Assay, Western Blot, Cell Culture, Generated, Infection, Control, Incubation, Staining

Fibroblast mTOR/PPARγ dependent HGF production promotes tubular cell survival. a Western blot analyses showing the abundance of PPARγ in primary cultured Rheb−/−, Tsc1−/−, and Rictor−/− kidney fibroblasts, respectively. b Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in primary cultured kidney fibroblasts. *P < 0.05 versus cells infected with adenovirus carrying GFP, n = 4. n = 4 refers to four independent repeats. c–e Western blotting analyses showing the abundance of p-c-met (Y1234/Y1235) and p-ERK1/2 (T202/Y204) as indicated. GAPDH was probed to show the equal loading. f Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in NRK-49F cells. *P < 0.05 versus vehicle-treated cells, n = 3. n = 3 refers to three independent repeats. NRK-49F cells were pretreated with Pioglitazone for 24 h. g NRK-52E cells were treated with staurosporine (1 μM) for different duration as indicated. Western blot analyses showing the abundance of cleaved caspase 3. h Real-time qRT-PCR analysis showing the mRNA abundance Hgf in NRK-49F cells transfected with scramble or HGF siRNA as indicated. *P < 0.05 versus cells transfected with scramble siRNA, n = 3. n = 3 refers to three independent repeats. i, j NRK-52E cells were treated with staurosporine (1 μM) for different duration as indicated. Western blotting analysis showing that knocking down Hgf in NRK-49F cells (i) or blockade of tubular cell c-met signaling (j) could aggravate staurosporine-induced NRK-52E cell apoptosis. k, l NRK-52E cells were treated with staurosporine (1 μM) for 3 h. Representative immunofluorescent staining images for cleaved caspase 3 among groups as indicated. Scale bar = 20 µm. m, n Quantitative determination of cleaved caspase 3+ cells among groups as indicated. Data are presented as the percentage of the counted cells. *P < 0.05 versus vehicle-treated cells, n = 3; #P < 0.05 versus staurosporine-treated cells, n = 3. n = 3 refers to three independent repeats. CM conditioned media

Journal: Cell Death and Differentiation

Article Title: Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury

doi: 10.1038/s41418-019-0336-3

Figure Lengend Snippet: Fibroblast mTOR/PPARγ dependent HGF production promotes tubular cell survival. a Western blot analyses showing the abundance of PPARγ in primary cultured Rheb−/−, Tsc1−/−, and Rictor−/− kidney fibroblasts, respectively. b Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in primary cultured kidney fibroblasts. *P < 0.05 versus cells infected with adenovirus carrying GFP, n = 4. n = 4 refers to four independent repeats. c–e Western blotting analyses showing the abundance of p-c-met (Y1234/Y1235) and p-ERK1/2 (T202/Y204) as indicated. GAPDH was probed to show the equal loading. f Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in NRK-49F cells. *P < 0.05 versus vehicle-treated cells, n = 3. n = 3 refers to three independent repeats. NRK-49F cells were pretreated with Pioglitazone for 24 h. g NRK-52E cells were treated with staurosporine (1 μM) for different duration as indicated. Western blot analyses showing the abundance of cleaved caspase 3. h Real-time qRT-PCR analysis showing the mRNA abundance Hgf in NRK-49F cells transfected with scramble or HGF siRNA as indicated. *P < 0.05 versus cells transfected with scramble siRNA, n = 3. n = 3 refers to three independent repeats. i, j NRK-52E cells were treated with staurosporine (1 μM) for different duration as indicated. Western blotting analysis showing that knocking down Hgf in NRK-49F cells (i) or blockade of tubular cell c-met signaling (j) could aggravate staurosporine-induced NRK-52E cell apoptosis. k, l NRK-52E cells were treated with staurosporine (1 μM) for 3 h. Representative immunofluorescent staining images for cleaved caspase 3 among groups as indicated. Scale bar = 20 µm. m, n Quantitative determination of cleaved caspase 3+ cells among groups as indicated. Data are presented as the percentage of the counted cells. *P < 0.05 versus vehicle-treated cells, n = 3; #P < 0.05 versus staurosporine-treated cells, n = 3. n = 3 refers to three independent repeats. CM conditioned media

Article Snippet: After blocking with 2% normal donkey serum for 60 min, the slides were immunostained with antibodies against Gli1 (cat: 388516, RD Systems), Fsp1 (cat: NB100-55404, Novus), PDGFRβ (cat:14-1402, eBioscience), p-Akt (Ser473) (cat: 3868, Cell Signaling Technology), p-S6 (cat: 4858, Cell Signaling Technology), Rheb (cat: ab25873, abcam), Tsc1 (cat: 4906, Cell Signaling Technology), Rictor (cat: A300-459A, Bethyl Laboratories), cleaved caspase 3 (cat: 9664, Cell Signaling Technology), Ly6b (cat: MCA771G, AbD Serotec, Raleigh, NC), and CD3 (cat: 555273, BD Pharmingen), respectively.

Techniques: Western Blot, Cell Culture, Quantitative RT-PCR, Infection, Transfection, Staining

MTOR regulates PPARγ/HGF expression in kidney fibroblasts in mice. a, c, e Western blot analyses showing the PPARγ abundance in the sham and IRI kidneys from the knockouts and littermate controls. Numbers indicate each individual animal within each group (left). The graphs showing the quantification of the PPARγ in the IRI and sham kidneys. *P < 0.05 versus littermate controls, #P < 0.05 versus littermate controls after IRI, n = 5. b, d, f Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in the knockout and littermate control kidneys. *P < 0.05 versus WT mice, n = 5–6. g–i Immunostaining showing PPARγ in the interstitial cells among groups as indicated. The asterisk indicates both Gli1- and PPARγ-positive cells in the Rheb+/+, Rictor+/+, and Tsc1−/− kidneys. The arrow indicates Gli1-positive but PPARγ-negative cells in the Rheb−/−, Rictor−/−, and Tsc1+/+ kidneys. Scale bar = 20 µm

Journal: Cell Death and Differentiation

Article Title: Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury

doi: 10.1038/s41418-019-0336-3

Figure Lengend Snippet: MTOR regulates PPARγ/HGF expression in kidney fibroblasts in mice. a, c, e Western blot analyses showing the PPARγ abundance in the sham and IRI kidneys from the knockouts and littermate controls. Numbers indicate each individual animal within each group (left). The graphs showing the quantification of the PPARγ in the IRI and sham kidneys. *P < 0.05 versus littermate controls, #P < 0.05 versus littermate controls after IRI, n = 5. b, d, f Real-time qRT-PCR analysis showing the mRNA abundance for Hgf in the knockout and littermate control kidneys. *P < 0.05 versus WT mice, n = 5–6. g–i Immunostaining showing PPARγ in the interstitial cells among groups as indicated. The asterisk indicates both Gli1- and PPARγ-positive cells in the Rheb+/+, Rictor+/+, and Tsc1−/− kidneys. The arrow indicates Gli1-positive but PPARγ-negative cells in the Rheb−/−, Rictor−/−, and Tsc1+/+ kidneys. Scale bar = 20 µm

Article Snippet: After blocking with 2% normal donkey serum for 60 min, the slides were immunostained with antibodies against Gli1 (cat: 388516, RD Systems), Fsp1 (cat: NB100-55404, Novus), PDGFRβ (cat:14-1402, eBioscience), p-Akt (Ser473) (cat: 3868, Cell Signaling Technology), p-S6 (cat: 4858, Cell Signaling Technology), Rheb (cat: ab25873, abcam), Tsc1 (cat: 4906, Cell Signaling Technology), Rictor (cat: A300-459A, Bethyl Laboratories), cleaved caspase 3 (cat: 9664, Cell Signaling Technology), Ly6b (cat: MCA771G, AbD Serotec, Raleigh, NC), and CD3 (cat: 555273, BD Pharmingen), respectively.

Techniques: Expressing, Western Blot, Quantitative RT-PCR, Knock-Out, Control, Immunostaining

Osteoblast adhesion and survival are markedly reduced and Rictor expression is downregulated with aging in vitro and in vivo . ( a ) Representative immunohistochemical (IHC) staining for osteocalcin (OCN) from 3-month-old and 16-month-old mice ( n =6). Arrow, osteoblast; BS, bone surface; scale bar, 50 μ m; * P <0.01 versus 3M. ( b ) SEM image of femora trabecular bones from 3- and 16-month-old mice. Upper panel showed less and thinner trabecula bone in 16-month-old mice. Black arrow, osteoblasts or osteocytes, up panel scale bar, 500 μ m; lower panel scale bar, 50 μ m. ( c ) Photomicrographs of fluorescent calcein staining of 3- and 16-month-old mice and quantification of mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR) and MAR/osteoblast. Arrow: bone formation surface; scale bar, 20 μ m ( n =3 * P <0.01 versus 3M). ( d ) Cell adhesion analyses of calvarial osteoblast cultures from 3- and 16-month-old mice with (lower panel) or without (upper panel) matrigel in the plate ( n =3 * P <0.01 versus 3M). ( e ) Representative photomicrographs of bone nodule formation in MSC cultures from 3- and 16-month-old mice. Scale bar, 400 μ m. ( f ) Western blot analysis of cleaved-poly ADP-ribose polymerase (PARP) in lysates of trabecular bone dissected from femora of 3- and 16-month-old mice. ( g ) Western blot analysis of Rictor and P-Akt(S473) expression in lysates of trabecular bone from 3- and 16-month-old mice. ( h ) Western blot analysis of mTOR, Rictor, Raptor and P-Akt(S473) expression in lysates of lung, spleen and kidney from 3- and 16-month-old mice. ( i ) Western blot analysis of Rictor, mTOR, Raptor, osteocalcin (OCN) and P-Akt(S473) expression in primary calvarial osteoblasts from 3- and 16-month-old mice

Journal: Cell Death & Disease

Article Title: Loss of Rictor with aging in osteoblasts promotes age-related bone loss

doi: 10.1038/cddis.2016.249

Figure Lengend Snippet: Osteoblast adhesion and survival are markedly reduced and Rictor expression is downregulated with aging in vitro and in vivo . ( a ) Representative immunohistochemical (IHC) staining for osteocalcin (OCN) from 3-month-old and 16-month-old mice ( n =6). Arrow, osteoblast; BS, bone surface; scale bar, 50 μ m; * P <0.01 versus 3M. ( b ) SEM image of femora trabecular bones from 3- and 16-month-old mice. Upper panel showed less and thinner trabecula bone in 16-month-old mice. Black arrow, osteoblasts or osteocytes, up panel scale bar, 500 μ m; lower panel scale bar, 50 μ m. ( c ) Photomicrographs of fluorescent calcein staining of 3- and 16-month-old mice and quantification of mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR) and MAR/osteoblast. Arrow: bone formation surface; scale bar, 20 μ m ( n =3 * P <0.01 versus 3M). ( d ) Cell adhesion analyses of calvarial osteoblast cultures from 3- and 16-month-old mice with (lower panel) or without (upper panel) matrigel in the plate ( n =3 * P <0.01 versus 3M). ( e ) Representative photomicrographs of bone nodule formation in MSC cultures from 3- and 16-month-old mice. Scale bar, 400 μ m. ( f ) Western blot analysis of cleaved-poly ADP-ribose polymerase (PARP) in lysates of trabecular bone dissected from femora of 3- and 16-month-old mice. ( g ) Western blot analysis of Rictor and P-Akt(S473) expression in lysates of trabecular bone from 3- and 16-month-old mice. ( h ) Western blot analysis of mTOR, Rictor, Raptor and P-Akt(S473) expression in lysates of lung, spleen and kidney from 3- and 16-month-old mice. ( i ) Western blot analysis of Rictor, mTOR, Raptor, osteocalcin (OCN) and P-Akt(S473) expression in primary calvarial osteoblasts from 3- and 16-month-old mice

Article Snippet: Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipo2000 (Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Techniques: Expressing, In Vitro, In Vivo, Immunohistochemical staining, Immunohistochemistry, Staining, Western Blot

Rictor is a target of miR-218 in osteoblasts. ( a ) Real-time PCR analysis of 13 miRNAs expression in trabecular bone from 3- and 16-month-old mice ( n =6). * P <0.01 versus 3M. ( b ) Western blot analysis of Rictor, p-Paxillin(Y118) and P-Akt(S473) expression in osteoblasts transfected with miR-218 mimics and miR-218 inhibitors. ( c ) The putative miR-218 binding site in the Rictor 3′ UTR. ( d ) Luciferase activity in MC3T3-E1 cells co-transfected with miR-218 mimics or negative control (NC) and the indicated 3′ UTR-driven reporter constructs ( n =3). * P <0.01 versus NC; ** P <0.05 versus NC

Journal: Cell Death & Disease

Article Title: Loss of Rictor with aging in osteoblasts promotes age-related bone loss

doi: 10.1038/cddis.2016.249

Figure Lengend Snippet: Rictor is a target of miR-218 in osteoblasts. ( a ) Real-time PCR analysis of 13 miRNAs expression in trabecular bone from 3- and 16-month-old mice ( n =6). * P <0.01 versus 3M. ( b ) Western blot analysis of Rictor, p-Paxillin(Y118) and P-Akt(S473) expression in osteoblasts transfected with miR-218 mimics and miR-218 inhibitors. ( c ) The putative miR-218 binding site in the Rictor 3′ UTR. ( d ) Luciferase activity in MC3T3-E1 cells co-transfected with miR-218 mimics or negative control (NC) and the indicated 3′ UTR-driven reporter constructs ( n =3). * P <0.01 versus NC; ** P <0.05 versus NC

Article Snippet: Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipo2000 (Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Western Blot, Transfection, Binding Assay, Luciferase, Activity Assay, Negative Control, Construct

miR-218 represses osteoblast adhesion and survival by targeting Rictor. ( a ) Adhesion analysis of MC3T3-E1 cells transfected with miR-218 mimics, miR-218 inhibitors and NCs ( n =3). * P <0.01, ** P <0.05. ( b ) AnnexinV analysis of apoptosis in MC3T3-E1 cells transfected with miR-218 mimics or miR-218 inhibitor and serum-starved for 48 h ( n =3). * P <0.01, ** P <0.05. ( c ) Western blot analysis of Rictor, p-Paxillin(Y118), Runx2 and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 mimics. ( d ) Western blot analysis of Rictor, p-Paxillin(Y118), Runx2 and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 inhibitor or NCs. ( e ) Western blot analysis of Rictor, p-Paxillin(Y118) and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vectors. ( f ) Adhesion analysis of MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vector ( n =3). * P <0.01, ** P <0.05. ( g ) AnnexinV analysis of apoptosis in MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vector ( n =3); * P <0.01, ** P <0.05

Journal: Cell Death & Disease

Article Title: Loss of Rictor with aging in osteoblasts promotes age-related bone loss

doi: 10.1038/cddis.2016.249

Figure Lengend Snippet: miR-218 represses osteoblast adhesion and survival by targeting Rictor. ( a ) Adhesion analysis of MC3T3-E1 cells transfected with miR-218 mimics, miR-218 inhibitors and NCs ( n =3). * P <0.01, ** P <0.05. ( b ) AnnexinV analysis of apoptosis in MC3T3-E1 cells transfected with miR-218 mimics or miR-218 inhibitor and serum-starved for 48 h ( n =3). * P <0.01, ** P <0.05. ( c ) Western blot analysis of Rictor, p-Paxillin(Y118), Runx2 and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 mimics. ( d ) Western blot analysis of Rictor, p-Paxillin(Y118), Runx2 and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 inhibitor or NCs. ( e ) Western blot analysis of Rictor, p-Paxillin(Y118) and p-Akt(S473) expression in MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vectors. ( f ) Adhesion analysis of MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vector ( n =3). * P <0.01, ** P <0.05. ( g ) AnnexinV analysis of apoptosis in MC3T3-E1 cells transfected with miR-218 mimics and/or Rictor-expressing vector ( n =3); * P <0.01, ** P <0.05

Article Snippet: Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipo2000 (Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Techniques: Transfection, Western Blot, Expressing, Plasmid Preparation

ROS stimulates miR-218 to downregulate Rictor in aged mice osteoblast. ( a ) ROS levels in trabecular bones of 3- and 16-month-old mice ( n =6); * P <0.01 compared with 3-month-old mice. ( b ) Effect of H 2 O 2 (1 μ M) on miR-218 expression in MC3T3-E1 cells ( n =3). * P <0.01 versus controls. ( c ) Western blot analysis of Rictor, mTOR and Raptor expression in MC3T3-E1 cells treated with H 2 O 2 (5, 10 μ M) for 48 h. ( d ) Effect of H 2 O 2 (1 μ M for 24 h) on MC3T3-E1 cell adhesion ( n =3). * P <0.01 versus controls. ( e ) Effect of H 2 O 2 (10 μ M for 36 h) and on MC3T3-E1 cell apoptosis( n =3). * P <0.01 versus controls

Journal: Cell Death & Disease

Article Title: Loss of Rictor with aging in osteoblasts promotes age-related bone loss

doi: 10.1038/cddis.2016.249

Figure Lengend Snippet: ROS stimulates miR-218 to downregulate Rictor in aged mice osteoblast. ( a ) ROS levels in trabecular bones of 3- and 16-month-old mice ( n =6); * P <0.01 compared with 3-month-old mice. ( b ) Effect of H 2 O 2 (1 μ M) on miR-218 expression in MC3T3-E1 cells ( n =3). * P <0.01 versus controls. ( c ) Western blot analysis of Rictor, mTOR and Raptor expression in MC3T3-E1 cells treated with H 2 O 2 (5, 10 μ M) for 48 h. ( d ) Effect of H 2 O 2 (1 μ M for 24 h) on MC3T3-E1 cell adhesion ( n =3). * P <0.01 versus controls. ( e ) Effect of H 2 O 2 (10 μ M for 36 h) and on MC3T3-E1 cell apoptosis( n =3). * P <0.01 versus controls

Article Snippet: Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipo2000 (Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Techniques: Expressing, Western Blot

ROS scavenger reduces miR-218 and Rictor expression and aged-related bone loss in mice. ( a ) Western blot analysis of Rictor, Raptor and P-Akt(S473) expression in trabecular bone of 3-, 9- and 16-month-old mice. ( b ) Trabecular bone ROS levels in 9-month-old mice treated with N-acetyl- l -cysteine (NAC; 2 mg/ml) or vehicle for 7 months ( n =10). * P <0.01 versus controls. ( c ) Representative micro-CT scans of vertebrae from mice described in ( b ). ( d – g ) Trabecular bone BV/TV, BMD, Tb.Sp and Tb.N in mice described in ( c ) ( n =10); * P <0.01 versus controls. ( h , i ) Oestocalcin IHC ( h ) or TRAP ( i ) staining of distal femora from mice described in ( b ). Scale bar, 50 μ m; * P <0.01 versus controls. ( j ) Real-time PCR analysis of miR-218 expression in trabecular bones of mice described in ( b )( n =10). * P <0.01 versus controls. ( k ) Westem bolt analysis of c-PARP expression in trabecular bones of mice described in (b). ( l ) Western blot analysis of Rictor, Raptor and P-Akt(S473) expression in trabecular bones of mice described in ( b ). ( m ) A schematic model depicting that the upregulation of miR-218 and loss of Rictor with aging induces the pathogenesis of age-related bone loss

Journal: Cell Death & Disease

Article Title: Loss of Rictor with aging in osteoblasts promotes age-related bone loss

doi: 10.1038/cddis.2016.249

Figure Lengend Snippet: ROS scavenger reduces miR-218 and Rictor expression and aged-related bone loss in mice. ( a ) Western blot analysis of Rictor, Raptor and P-Akt(S473) expression in trabecular bone of 3-, 9- and 16-month-old mice. ( b ) Trabecular bone ROS levels in 9-month-old mice treated with N-acetyl- l -cysteine (NAC; 2 mg/ml) or vehicle for 7 months ( n =10). * P <0.01 versus controls. ( c ) Representative micro-CT scans of vertebrae from mice described in ( b ). ( d – g ) Trabecular bone BV/TV, BMD, Tb.Sp and Tb.N in mice described in ( c ) ( n =10); * P <0.01 versus controls. ( h , i ) Oestocalcin IHC ( h ) or TRAP ( i ) staining of distal femora from mice described in ( b ). Scale bar, 50 μ m; * P <0.01 versus controls. ( j ) Real-time PCR analysis of miR-218 expression in trabecular bones of mice described in ( b )( n =10). * P <0.01 versus controls. ( k ) Westem bolt analysis of c-PARP expression in trabecular bones of mice described in (b). ( l ) Western blot analysis of Rictor, Raptor and P-Akt(S473) expression in trabecular bones of mice described in ( b ). ( m ) A schematic model depicting that the upregulation of miR-218 and loss of Rictor with aging induces the pathogenesis of age-related bone loss

Article Snippet: Cells were transfected with a Rictor expression vector (pRK5-myc-Rictor, addgene, cat #1860), or with 100 nM miR-218 mimic, miR-218 inhibitor or scramble Control oligo using the transfection agent lipo2000 (Invitrogen, Carlsbad, Canada) according to the manufacturer's instructions.

Techniques: Expressing, Western Blot, Micro-CT, Staining, Real-time Polymerase Chain Reaction

Figure 3. mTORC2, AKT, and GSK3b Signaling Components Are Present in Mitochondria-ER Junctions (A) Immunoblots of MEJ, PM, and EGC fractions and total lysate (T) from Jurkat T cells. Blots were probed with mTOR, RICTOR, RAPTOR, and AKT antibodies. COX IV was used as loading and fraction-validation control (representative of n = 3 independent experiments). (B) Immunoblots of EGC and MEJ fractions from NV and EM human CD8+ T cells probed with antibodies specific for RICTOR and mTOR. GRP75 was used to validate the respective fractions (representative of n = 2 independent samples, each sample consisted of 4 3 107 sorted cells, pooled from 2–4 donors). (C) Immunoblot analysis of EGC and MEJ fractions from bulk CD8+ T cells treated with non-loaded control beads (–) or activated with a-CD3 and a-CD28 mAb-loaded beads (+) for 2 hr. Blots were probed with mTOR and RICTOR antibodies. Cox IV was used as fraction validation control (representative of n = 3 independent experiments). (D) Left, immunoblot analysis of MEJ fractions from wild-type (WT) and rictor KO memory CD8+ T cells re-stimulated with OVA peptide for 1 hr (+) or from non-activated counterparts (–). Blots were probed for total Akt, pAkt-S473, pAkt-T308, and Cox IV. Right, quantification was performed by normalization of targets to Cox IV. Bar graphs show fold change in Akt phosphorylation following activation relative to non-activated controls (n = 3 independent experiments). (E and F) Summary of metabolic flux analysis on EM CD8+ T cells activated and assayed as in Figure 1A. Cells were treated with inhibitors of mTOR (OSI-027, 10 mM, and KU0063794, 10 mM) (E) or AKT (Akti, 10 mM, and MK2206, 10 mM) (F). Bar graphs show basal and maximal respiration (n = 4–8 donors). (G) Immunoblot analysis of total cell lysates from EM CD8+ T cells activated for 2 hr with a-CD3 and a-CD28 mAb loaded beads only or similarly activated in presence of nocodazole (10 mM). Bar graph shows AKT-Ser473 phosphorylation normalized to actin (n = 3 independent experiments). (H) Immunoblots of MEJ and PM fractions from Jurkat T cells. Blots were probed with GSK3b and COX IV antibodies (representative of n = 3 independent experiments). (I) Immunoblots of MEJ and EGC fractions from bulk CD8+ T cells either left unstimulated (–) or activated (+) with a-CD3 and a-CD28 mAb-loaded beads for 2 hr. Blots were probed for total GSK3b, pGSK3b Ser9, and COX IV (representative of n = 3 donors). (J) Left, immunoblot analysis of WT and rictor KO memory OT-I cells activated as in (D). MEJ fractions were probed for Gsk-3b, pGsk-3b Ser9, and Cox IV. Right, bar graphs display fold change in phosphoprotein levels relative to non-activated controls (n = 3 independent experiments). Data are presented as mean ± SEM. Two-tailed paired Student’s t test (D–G, J) were used to compare groups. *p < 0.05, **p < 0.01, ns, not significant. See also Figure S3.

Journal: Immunity

Article Title: Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8 + T Cells.

doi: 10.1016/j.immuni.2018.02.012

Figure Lengend Snippet: Figure 3. mTORC2, AKT, and GSK3b Signaling Components Are Present in Mitochondria-ER Junctions (A) Immunoblots of MEJ, PM, and EGC fractions and total lysate (T) from Jurkat T cells. Blots were probed with mTOR, RICTOR, RAPTOR, and AKT antibodies. COX IV was used as loading and fraction-validation control (representative of n = 3 independent experiments). (B) Immunoblots of EGC and MEJ fractions from NV and EM human CD8+ T cells probed with antibodies specific for RICTOR and mTOR. GRP75 was used to validate the respective fractions (representative of n = 2 independent samples, each sample consisted of 4 3 107 sorted cells, pooled from 2–4 donors). (C) Immunoblot analysis of EGC and MEJ fractions from bulk CD8+ T cells treated with non-loaded control beads (–) or activated with a-CD3 and a-CD28 mAb-loaded beads (+) for 2 hr. Blots were probed with mTOR and RICTOR antibodies. Cox IV was used as fraction validation control (representative of n = 3 independent experiments). (D) Left, immunoblot analysis of MEJ fractions from wild-type (WT) and rictor KO memory CD8+ T cells re-stimulated with OVA peptide for 1 hr (+) or from non-activated counterparts (–). Blots were probed for total Akt, pAkt-S473, pAkt-T308, and Cox IV. Right, quantification was performed by normalization of targets to Cox IV. Bar graphs show fold change in Akt phosphorylation following activation relative to non-activated controls (n = 3 independent experiments). (E and F) Summary of metabolic flux analysis on EM CD8+ T cells activated and assayed as in Figure 1A. Cells were treated with inhibitors of mTOR (OSI-027, 10 mM, and KU0063794, 10 mM) (E) or AKT (Akti, 10 mM, and MK2206, 10 mM) (F). Bar graphs show basal and maximal respiration (n = 4–8 donors). (G) Immunoblot analysis of total cell lysates from EM CD8+ T cells activated for 2 hr with a-CD3 and a-CD28 mAb loaded beads only or similarly activated in presence of nocodazole (10 mM). Bar graph shows AKT-Ser473 phosphorylation normalized to actin (n = 3 independent experiments). (H) Immunoblots of MEJ and PM fractions from Jurkat T cells. Blots were probed with GSK3b and COX IV antibodies (representative of n = 3 independent experiments). (I) Immunoblots of MEJ and EGC fractions from bulk CD8+ T cells either left unstimulated (–) or activated (+) with a-CD3 and a-CD28 mAb-loaded beads for 2 hr. Blots were probed for total GSK3b, pGSK3b Ser9, and COX IV (representative of n = 3 donors). (J) Left, immunoblot analysis of WT and rictor KO memory OT-I cells activated as in (D). MEJ fractions were probed for Gsk-3b, pGsk-3b Ser9, and Cox IV. Right, bar graphs display fold change in phosphoprotein levels relative to non-activated controls (n = 3 independent experiments). Data are presented as mean ± SEM. Two-tailed paired Student’s t test (D–G, J) were used to compare groups. *p < 0.05, **p < 0.01, ns, not significant. See also Figure S3.

Article Snippet: Cells were stained with antibodies against rictor (Atlas antibodies), KDEL motif (Abcam) or Gsk-3b (Abcam), labeled with the appropriate secondary antibodies, and counterstained with DAPI.

Techniques: Western Blot, Biomarker Discovery, Control, Phospho-proteomics, Activation Assay, Two Tailed Test